Maybe I could comment, not because I have a different opinion but to mention this. Under the national pharmaceutical strategy, which is a joint enterprise of the provincial and territorial governments and the federal government, moving toward a national formulary is one of the objectives of that strategy. I think it's fair to mention that while not all drug plans will access all of the drugs, given the nature of the beneficiaries that might be on that formulary, it's one element.
A second element worth mentioning is that even in the environment of an agreed-on national formulary, I think there will still be decisions made about access on an exceptional rate basis to certain products. I think it's what you've heard a little about here today.
Even if in the majority of cases the recommendations of the CDR are accepted, there still will be exceptions that need to be made, and there are good therapeutic reasons and good efficiency reasons for doing that. There will need to be decision-making structures in place to allow for expert advice to be received on a case-by-case basis to allow for those exceptions. But they would not detract from the value of a core national formulary. We will continue to use CDR, particularly as CDR expands into new indications for old drugs. But even more importantly, class reviews, which we expect will come on stream over the next few years, will significantly assist the eventual goal of a common core formulary.